Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs.

Antioxidants & Redox Signaling
Mary El KazziPaul Kenneth Witting

Abstract

Significance: Acute myocardial infarction (AMI) is a leading cause of death worldwide. Post-AMI survival rates have increased with the introduction of angioplasty as a primary coronary intervention. However, reperfusion after angioplasty represents a clinical paradox, restoring blood flow to the ischemic myocardium while simultaneously inducing ion and metabolic imbalances that stimulate immune cell recruitment and activation, mitochondrial dysfunction and damaging oxidant production. Recent Advances: Preclinical data indicate that these metabolic imbalances contribute to subsequent heart failure through sustaining local recruitment of inflammatory leukocytes and oxidative stress, cardiomyocyte death, and coronary microvascular disturbances, which enhance adverse cardiac remodeling. Both left ventricular dysfunction and heart failure are strongly linked to inflammation and immune cell recruitment to the damaged myocardium. Critical Issues: Overall, therapeutic anti-inflammatory and antioxidant agents identified in preclinical trials have failed in clinical trials. Future Directions: The versatile neutrophil-derived heme enzyme, myeloperoxidase (MPO), is gaining attention as an important oxidative mediator of reperfusion injury,...Continue Reading

References

Jun 1, 1985·Journal of the American College of Cardiology·G OlssonT Lundman
Aug 1, 1973·Journal of Molecular and Cellular Cardiology·D J HearseE B Chain
Jul 1, 1994·The Journal of Clinical Investigation·A DaughertyJ W Heinecke
Mar 15, 1996·The Journal of Clinical Investigation·L J HazellR Stocker
Mar 1, 1997·Journal of Leukocyte Biology·C C KingE L Thomas
Jul 22, 1997·Proceedings of the National Academy of Sciences of the United States of America·P H MaxwellP J Ratcliffe
Aug 8, 1997·The Journal of Biological Chemistry·T YinJ Whelan
Jun 6, 1998·Cardiovascular Research·P P de Tombe
Aug 26, 1998·The New England Journal of Medicine·S S GottliebR A Vogel
Jan 14, 1999·The New England Journal of Medicine·R Ross
Jan 5, 2000·American Heart Journal·L KyneJ Y Wei
Aug 22, 2001·American Journal of Physiology. Heart and Circulatory Physiology·T TsujiM Takaki
Sep 22, 2001·Archives of Biochemistry and Biophysics·R G MidwinterC C Winterbourn
Nov 16, 2001·American Journal of Physiology. Heart and Circulatory Physiology·T O NossuliM L Entman
Jun 29, 2002·Science·Jason P EiserichBruce A Freeman
Jul 5, 2002·The New England Journal of Medicine·Antonino BuffonAttilio Maseri
Oct 3, 2002·The Journal of Biological Chemistry·Renliang ZhangStanley L Hazen
Oct 4, 2002·Archives of Biochemistry and Biophysics·Hesham A SadekLuke I Szweda
Oct 24, 2003·The New England Journal of Medicine·Marie-Luise BrennanStanley L Hazen
Mar 20, 2004·Experimental & Molecular Medicine·Ji-Won LeeKyu-Won Kim
May 11, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yan HuangFrank J Giordano
Jul 13, 2004·The American Journal of Cardiology·Vivek RajagopalEric J Topol
Aug 12, 2004·Free Radical Biology & Medicine·Stephan BaldusThomas Münzel
Aug 25, 2004·Proceedings of the National Academy of Sciences of the United States of America·Constanze BergtJay W Heinecke
Aug 28, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Roland StockerJohn F Keaney
Aug 31, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S-T Joseph HuangLinda C Giudice
Sep 24, 2004·Physiological Reviews·Roland Stocker, John F Keaney
Feb 1, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Arun K ThukkaniDavid A Ford
Mar 26, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Stephen J Nicholls, Stanley L Hazen
May 25, 2005·Circulation·Timothy S McMillenRenee C LeBoeuf
Jun 30, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Victoria J AdlamIvan A Sammut

❮ Previous
Next ❯

Citations

Dec 23, 2020·Antioxidants·Wenjun Wang, Peter M Kang
Mar 18, 2021·Bulletin of Experimental Biology and Medicine·K V DergilevE V Parfenova
Jun 5, 2021·Journal of Molecular and Cellular Cardiology·Wan-Tseng HsuChii-Ming Lee

❮ Previous
Next ❯

Software Mentioned

SOLSTICE

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.